The 14th Meeting of the Singapore-Guangdong Collaboration Council is held in Guangzhou.

The 14th Meeting of the Singapore-Guangdong Collaboration Council (SGCC) was held on the morning of July 31 at the China-Singapore Guangzhou Knowledge City (CSGKC) International Convention and Exhibition Center in Guangzhou.

At the signing ceremony for the Guangdong-Singapore enterprise cooperation project on the spot, 20 MoUs were signed across various domains, including biomedicine, financial services, green development, agricultural technology, education talents, smart transportation and platform construction.

Michelle Chen, Co-founder & CEO of Biosyngen, noted that she is very honored, and it is her third time being listed in SGCC.Regarding the signing project of double resistance against autoimmunity, Miss Chen noted that people's lifespan is getting longer currently, which implies that the body machine will also break down. Everyone starts to pay attention to issues of autoimmunity such as lupus, rheumatoid arthritis, etc., which are all related to immunity.Miss Chen's company is partnering with the Agency for Science, Technology and Research Singapore to promote the project together and benefit the world.Biomedicine is one of the three pillar industries in the GBA. According to Miss Chen, the enterprise hopes to develop specific policy support for the GBA in the domains of new drug R&D accelerators, or subsidies, etc., for these original medicines.

Established in 2009, the Singapore-Guangdong Cooperation Council has become an effective platform for both sides to promote pragmatic cooperation. It has played an increasingly critical role in deepening exchanges and cooperation between Guangdong Province and Singapore.